First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat
ConclusionsVafidemstat displayed good safety and tolerability. This phase I trial confirmed KDM1A TE and CNS penetration and permitted characterization of platelet dynamics and selection of phase IIa doses.Trial registrationEUDRACT No. 2015-003721-33, filed 30 October 2015. (Source: CNS Drugs)
Source: CNS Drugs - March 23, 2021 Category: Neurology Source Type: research
Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox –Gastaut Syndrome
ConclusionsThe currently available data suggest that response to treatment with a highly purified, plant-derived CBD oil-based solution can be seen in patients across a broad range of epilepsy disorders and etiologies. The existing evidence can provide preliminary support for additional research. (Source: CNS Drugs)
Source: CNS Drugs - March 22, 2021 Category: Neurology Source Type: research
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
ConclusionsComorbidities, obesity, and Black/African ancestry, but not age, were associated with a higher risk of SARS-CoV-2 infection in PwMS. Interferons and glatiramer acetate were associated with a reduced COVID-19 risk, whereas anti-CD20 therapies were associated with an increased risk, within the treated MS cohort. COVID-19 safety reports for patients receiving Biogen MS therapies were consistent with the Explorys database and MS literature, illustrating the replicability and power of this approach. (Source: CNS Drugs)
Source: CNS Drugs - March 20, 2021 Category: Neurology Source Type: research
Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program
ConclusionsFindings from this study suggest that FEP patients with a gambling history, problematic or not, may be at increased risk of developing PBG when receiving aripiprazole. They also highlight the importance of systematically screening for PBG all individuals with psychotic disorders, as this comorbidity hinders recovery. While the results also add credence to a causal association between aripiprazole and PBG, further prospective studies are needed to address some of the limitations of this present study. (Source: CNS Drugs)
Source: CNS Drugs - March 13, 2021 Category: Neurology Source Type: research
Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report
ConclusionsEscitalopram monotherapy in acute MDD did not result in significant cognitive improvements. We provide novel evidence that escitalopram continuation in responders does not adversely affect cognition, but adjunctive aripiprazole in escitalopram non-responders worsens reaction time. Treatments targeting cognitive dysfunction are needed in MDD.ClinicalTrials.gov identifierNCT01655706; 2 August, 2012. (Source: CNS Drugs)
Source: CNS Drugs - March 8, 2021 Category: Neurology Source Type: research
